American Society of Hematology

Figure 2

$Figure 2. Comparison of de novo with transplanted Vk*MYC mice. (Left panel) A flow cytometric analysis of SPL (A) and BM (B) from a matching de novo Vk*MYC and transplant recipient mouse highlighting higher tumor burden and extramedullary MM in tVk*MYC mice. (Middle panel) Immunostaining of (A) SPL and (B) BM sections from de novo and tVk*MYC mice identify a high fraction of proliferating (Ki67+, blue) MM (CD138+, brown) cells in tVk*MYC mice only. Arrows highlight the rare double-positive cells in the de novo Vk*MYC mice. (B left panel) Cell-cycle analysis on CD138+ cells from BM of de novo and tVk*MYC mice. Values (%) ± SD from 3 independent experiments are given.$

Comparison of de novo with transplanted Vk*MYC mice. (Left panel) A flow cytometric analysis of SPL (A) and BM (B) from a matching de novo Vk*MYC and transplant recipient mouse highlighting higher tumor burden and extramedullary MM in tVk*MYC mice. (Middle panel) Immunostaining of (A) SPL and (B) BM sections from de novo and tVk*MYC mice identify a high fraction of proliferating (Ki67⁺, blue) MM (CD138⁺, brown) cells in tVk*MYC mice only. Arrows highlight the rare double-positive cells in the de novo Vk*MYC mice. (B left panel) Cell-cycle analysis on CD138⁺ cells from BM of de novo and tVk*MYC mice. Values (%) ± SD from 3 independent experiments are given.

This Feature Is Available To Subscribers Only